Section Arrow
ANAB.NASDAQ
- AnaptysBio
Quotes are at least 15-min delayed:2026/05/06 17:03 EDT
After Hours
Last
 67.36
0 (0.00%)
Bid
67.3
Ask
67.46
High 67.36 
Low 66.01 
Volume 14.74K 
Regular Hours (Closed)
Last
 67.36
-1.92 (-2.77%)
Day High 
72.2299 
Prev. Close
69.28 
1-M High
72.36 
Volume 
663.61K 
Bid
67.3
Ask
67.46
Day Low
67.04 
Open
69.08 
1-M Low
38.360984 
Market Cap 
2.02B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 63.03 
20-SMA 54.83 
50-SMA 45.99 
52-W High 72.36 
52-W Low 11.402444 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.46/-8.55
Enterprise Value
2.03B
Balance Sheet
Book Value Per Share
1.28
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
234.60M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ERNAErnexa Therapeutics Inc.6.04+2.05+51.38%0PE
After Hours 6.68 +0.64 +10.60%
MNKDMannKind Corp3.56+0.7+24.48%143PE
After Hours 3.2 -0.36 -10.11%
AVTXAvalo Therapeutics21.81+5.55+34.13%-- 
After Hours 21.54 -0.27 -1.24%
GERNGeron Corp1.58-0.07-4.24%-- 
After Hours 1.58 0 0.00%
IBRXImmunityBio8.38+0.8+10.55%-- 
After Hours 8.39 +0.01 +0.12%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.